Vasculitis
Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
A group of disorder caused by the
inflammation of blood vessels is known as vasculitis (plural: vasculitides),
also called angiitis. Vasculitis includes inflammation of arteries, veins,
and/or capillaries. The disease can affect both males and females equally
without any age specifications. Quite a
few forms of vasculitis are present, and their scientific characteristics can
vary considerably in terms of severity, symptoms, as well as the duration of
disease. It depends on the types of blood vessels that are affected by the
disease. Vasculitis is a disease which involves the immune system. Here, the
immune system stops offering defense aligned with infection and, consequently
it fights itself. The precise root of vasculitis is unknown; however, factors
triggering the disease include genetic makeup of an individual, blood cancers,
immune system diseases (e.g. rheumatoid arthritis), infections (e.g. hepatitis
B), and response to certain drugs. Inflammation of blood vessels may lead to
several complications. It may block the path of blood flow thereby causing
organs to dysfunction.
According to Vasculitis UK, major
cause of vasculitis may be hereditary or environmental. Moreover, there is a
lack of approved treatment from the regulatory bodies. According to National
Center for Biotechnology Information, in 2011, the therapy rituximab (Biogen
Idec/Genentech, Rituxan) happened to be the earliest and only FDA-approved
possibility for the treatment of vasculitis. This has encouraged the
governments and the manufacturers alike, for development of new drugs for
vasculitis treatment. Moreover, early detection is one of the key factors for
the treatment of the disease. Advent of technology and advanced diagnosis along
with support from governments and regulatory bodies around the world will fuel
the growth of the global vasculitis treatment market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/150
The American Heart Association
says even though it is not established that inflammation of arteries or veins
causes cardiovascular disease, however, inflammation is widespread for patients
with stroke and heart disease patients and is considered to be an atherogenic
(deposition of fat in arteries) response. As the number of cardio vascular
diseases in on the rise, patients with opt for diagnosis and treatment of
vasculitis. Although it is not proven that inflammation causes cardiovascular
disease, inflammation is common for heart disease and stroke patients and is
thought to be a sign or atherogenic response; this in turn will propel the
growth of the global vasculitis treatment market.
Increase in geriatric population
offers a promising future for vasculitis treatment market
According to Vasculitis UK,
usually the frequency of occurrence of vasculitis increases from the 50s;
however, but infants and young people can be affected as well. According to
Administration for Community Living, 46.2 million people in the U.S. were above
the age of 65 in 2014. It is estimated that by 2060 there will be around 98
million people falling under this age group. Additionally, latest scientific
developments have led to a significant increase in life expectancy around the
globe. As the geriatric population increase, so does the propensity of
occurrence of vasculitis. As patients have become health aware, and healthcare
spend has increased significantly, it can be projected that a part of it will
be spent on the diagnosis and treatment of vasculitis; thereby increasing the
global vasculitis treatment market.
Manufacturers around the world
are competing on the availability of technologically advanced drugs for the
treatment of vasculitis. Therefore, there is a significant increase in the
research and development spends incurred by the companies. Government support
is another positive factor that is in favor of the manufacturers. Some of the
companies operating in the global vasculitis treatment market are RNL BIO Co.,
Ltd., GlaxoSmithKline plc, Novartis AG, Troikaa Pharmaceuticals Ltd., Human
Genome Sciences, Inc.¸ Genentech, Inc., F. Hoffmann-La Roche Ltd., Anthera
Pharmaceuticals‚ Inc., and Teijin Pharma Limited.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/vasculitis-treatment-market-150
Key Developments
Major players in the market are
focused on approval and launch of novel therapeutics intended for the treatment
of various types of vasculitis. For instance, in July 2019, Pfizer Inc.
announced that its RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan
(rituximab), intended for the treatment of adult patients with microscopic
polyangiitis, received the U.S. Food and Drug Administration (FDA) approval.
Major institutes and universities
are focused on R&D activities related to the treatment of vasculitis. For
instance, in August 2019, researchers from Hospital El Bierzo and Burgos
University Hospital, Spain, suggested adoption of disease management based on
individual patient characteristics and levels of disease severity for the
treatment of vasculitis.
Similarly, in August 2019,
researchers from Osaka University Graduate School of Medicine, Japan found that
intravenous immunoglobulin was associated with rapid improvements in disease
activity and the related biomarkers in patients with active ANCA-associated
vasculitis.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/150
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200 Seattle,
WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment